Search results for "Repo"

showing 10 items of 2753 documents

Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gef…

2019

The management of multiple primary cancers, an event not so infrequent in oncology practice, is a critical issue due to the lack of literature. In this study, we reported the case of a patient with non-small cell metastatic lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) who received gefitinib in combination with gemcitabine plus nab-paclitaxel and with mFOLFOX6 in first and second line, respectively. It achieved a progression-free survival and a28-months overall survival (OS) for NSCLC and PFS-1 and OS of 20 and 13 months, respectively for PDAC. Moreover, the combination of gefitinib and chemotherapy treatmentsshowed a good safety profile. Given the insignificant frequency …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentCellgefitinibpancreatic ductal adenocarcinomaCase Reportmedicine.disease_causechemotherapylcsh:RC254-28203 medical and health sciences0302 clinical medicineGefitinibInternal medicinemedicineLung cancerSurvival ratenon-small cell lung cancerChemotherapyMutationbusiness.industrydouble primary cancersLong Term Survivormedicine.diseaseDouble primary cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensGemcitabine030104 developmental biologymedicine.anatomical_structureOncologyB7-H3030220 oncology & carcinogenesisbusinessmedicine.drugCancers
researchProduct

Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report

2021

Pembrolizumab (mAb to PD-1) has been recently approved for the therapy of pretreated urothelial cancer. Despite the efficacy, it is often accompanied by unpredictable and sometime severe immune-related (ir) adverse events (AEs). Here, we report the clinical and immune–biological characterization of a patient with a metastatic bladder cancer who developed myositis signs (M) and a myasthenia-like syndrome (MLS) during treatment with pembrolizumab. The patient presented an autoimmunity-associated HLA haplotype (HLA-A*02/HLA-B*08/HLA-C*07/HLA-DRB1*03) and experienced an increase in activated CD8 T-cells along the treatment. The symptomatology regressed after pembrolizumab discontinuation and a …

0301 basic medicineOncologyMaleCase ReportAutoimmunityPembrolizumabPD1-checkpoint inhibitorsmedicine.disease_causeAutoimmunity0302 clinical medicineAntineoplastic Agents ImmunologicalBiology (General)HLA AntigenMyositiPD1-checkpoint inhibitorSpectroscopyMyositisGeneral MedicineComputer Science ApplicationsMyasthenia GraviChemistryPyridostigmineurothelial cancer030220 oncology & carcinogenesisUrinary Bladder NeoplasmClass-I/II HLAMyastheniamedicine.drugHumanmedicine.medical_specialtyQH301-705.5PrognosiHuman leukocyte antigenAntibodies Monoclonal HumanizedCatalysisInorganic Chemistry03 medical and health sciencesInternal medicinemedicinePhysical and Theoretical ChemistryAdverse effectMolecular BiologyQD1-999Agedbusiness.industryOrganic ChemistryCancermedicine.diseaseDiscontinuation030104 developmental biologybusiness
researchProduct

Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After All…

2020

Currently, the prognosis of Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients relapsing after an allogenic hematopoietic stem cell transplantation (allo-SCT) remains poor, with few therapeutic options available. Here we present the case of a 32 years old patient with dasatinib-resistant post-transplant molecular relapse of ALL, who received, as second-line therapy, the combination of ponatinib and donor lymphocyte infusion (DLI). The therapy was safe and the patient achieved a sustained minimal residual disease negative disease, still ongoing after 22 months, which was accompanied by several changes in the immune populations distribution within the bone marrow (i.e., the increase in the C…

0301 basic medicineOncologymedicine.medical_specialtyCancer Researchmedicine.medical_treatmentT lymphocytesCase ReportHematopoietic stem cell transplantationlcsh:RC254-282Donor lymphocyte infusionbone marrow microenviroment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineacute lymhoblastic leukemiaInternal medicinehemic and lymphatic diseasesT lymphocytemedicineponatinibbusiness.industryPonatinibDonor Lymphocyteslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDasatinib030104 developmental biologymedicine.anatomical_structurechemistryOncology030220 oncology & carcinogenesisdonor lymphocyte infusion (DLI)Bone marrowStem cellbusinessCD8medicine.drugFrontiers in Oncology
researchProduct

CIMT 2018: Pushing frontiers in cancer immunotherapy — Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy

2018

ABSTRACT The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe’s largest meeting series of its kind, took place in Mainz, Germany from 15–17 May, 2018. Cutting-edge advancements in cancer immunotherapy were discussed among more than 700 scientists under the motto “Pushing Frontiers in Cancer Immunotherapy”. This meeting report is a summary of some of the CIMT 2018 highlights.

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyMeeting Reportcombination therapyCell therapy03 medical and health sciencesCancer immunotherapyInternal medicineNeoplasmsmedicineTumor MicroenvironmentImmunology and AllergyAnimalsHumansPersonalized therapytumor vaccinationPharmacologypersonalized therapyTumor microenvironmentcancer immunotherapybusiness.industryVaccinationCIMTcellular therapyCongresses as TopicXenograft Model Antitumor AssaysDisease Models Animal030104 developmental biologycheckpoint blockadeDrug Therapy CombinationImmunotherapybusinessHuman Vaccines & Immunotherapeutics
researchProduct

CIMT 2016: Mechanisms of efficacy in cancer immunotherapy — Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10–12 2…

2016

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyMeeting Reportcombination therapyCell therapy03 medical and health sciencesCancer immunotherapyInternal medicineantibodiestumor microenvironmentImmunology and AllergyMedicinetumor vaccinationPersonalized therapypersonalized therapyPharmacologyTumor microenvironmentcancer immunotherapybusiness.industryCIMTcellular therapy030104 developmental biologyImmunologycheckpoint blockadebusinessHuman Vaccines & Immunotherapeutics
researchProduct

CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy

2015

The 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) brought together more than 800 scientists in Mainz, Germany, from May 11–13, 2015, to present and discuss current research...

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyMeeting Reportcombination therapyCell therapy03 medical and health sciencesCancer immunotherapyInternal medicinemedicineImmunology and Allergytumor microenvironmentPersonalized therapytumor vaccinationPharmacologypersonalized therapyTumor microenvironmentcancer immunotherapybusiness.industryCIMTcellular therapy030104 developmental biologyImmunologybusinessHuman Vaccines & Immunotherapeutics
researchProduct

CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy

2017

The 15th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) took place May 10–11, 2017, Mainz, Germany during which scientists and CIMT members from all over the world not only celeb...

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyPhysiologyMeeting Reportcombination therapyCell therapy03 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicinemedicineImmunology and Allergyantibodiestumor microenvironmentPersonalized therapytumor vaccinationPharmacologypersonalized therapycancer immunotherapybusiness.industryCIMTcellular therapy030104 developmental biology030220 oncology & carcinogenesischeckpoint blockadebusinessHuman Vaccines & Immunotherapeutics
researchProduct

Consequences of organ choice in describing bacterial pathogen assemblages in a rodent population

2017

SUMMARYHigh-throughput sequencing technologies now allow for rapid cost-effective surveys of multiple pathogens in many host species including rodents, but it is currently unclear if the organ chosen for screening influences the number and identity of bacteria detected. We used 16S rRNA amplicon sequencing to identify bacterial pathogens in the heart, liver, lungs, kidneys and spleen of 13 water voles (Arvicola terrestris) collected in Franche-Comté, France. We asked if bacterial pathogen assemblages within organs are similar and if all five organs are necessary to detect all of the bacteria present in an individual animal. We identified 24 bacteria representing 17 genera; average bacterial…

0301 basic medicineOperational taxonomic unitMESH: Sequence Analysis DNAEpidemiologyMESH : PrevalenceMESH : Tissue DistributionRodent DiseasesRNA Ribosomal 16Sbacterial pathogensPrevalenceMESH : DNA BacterialTissue DistributionMESH: AnimalsPathogen[SDV.EE]Life Sciences [q-bio]/Ecology environmenteducation.field_of_studybiologyEcologyArvicolinaeMicrobiotaMESH : Rodent Diseases3. Good healthMESH: RNA Ribosomal 16SInfectious DiseasesArvicolinaeFrancerodent-borne pathogenDNA Bacterial030106 microbiologyPopulationShort ReportZoology[ SDV.EE ] Life Sciences [q-bio]/Ecology environment03 medical and health sciencesAnimalsMESH: MicrobiotaMESH : BacteriaMESH: Tissue DistributionArvicola terrestriseducationMESH : FranceMESH: Prevalence[ SDE.BE ] Environmental Sciences/Biodiversity and EcologyBacteriaHost (biology)tissue selectionBacteria PresentSequence Analysis DNAMESH: Arvicolinaebiology.organism_classificationMESH: DNA BacterialMESH: FranceMESH : ArvicolinaeMESH : RNA Ribosomal 16SMESH: BacteriaHigh-Throughput Sequencing030104 developmental biologyMESH : MicrobiotaSpecies richnessMESH: Rodent DiseasesMESH : Animals[SDE.BE]Environmental Sciences/Biodiversity and EcologyBacteriaMESH : Sequence Analysis DNA
researchProduct

Multidisciplinary surgical management of Cowden syndrome: Report of a case

2016

Cowden’s Syndrome (CS) is a rare congenital autosomal dominant disorder that affects around 1/200000 patients with an incomplete penetrance and variable expressivity, characterized by alterations in a tumor suppressor gene. A 14-year-old Caucasian male patient came to the attention of the authors complaining of palm nodules, gingival bleeding and painful pedunculated lesions on the lips and on the labial side of anterior sextants. After genetic investigation the final diagnosis of a Cowden Syndrome was made. The lesions were surgically removed under general anesthesia and no clinical signs of recurrence were found three months after surgical excision. Considering the severe symptoms of the …

0301 basic medicineOral papillomatosismedicine.medical_specialtyOdontologíaOral papillomatosisCancer predispositionSettore MED/28 - MALATTIE ODONTOSTOMATOLOGICHE03 medical and health sciences0302 clinical medicineCancer predisposition; Case report; Early diagnosis; Multiple hamartoma syndrome; Oral papillomatosis; Dentistry (all)Case reportmedicineGeneral Dentistrybusiness.industryCancer predispositionMultiple hamartoma syndromeMultiple hamartoma syndrome030206 dentistryCowden syndromeEarly diagnosismedicine.diseaseCiencias de la saludPenetranceDermatologySurgery030104 developmental biologyMale patientDentistry (all)UNESCO::CIENCIAS MÃ DICASOdontostomatology for the Disabled or Special PatientsSurgical excision:CIENCIAS MÃ DICAS [UNESCO]businessJournal of Clinical and Experimental Dentistry
researchProduct

Sympathetic, metabolic adaptations, and oxidative stress in autism spectrum disorders: How far from physiology?

2018

Autism spectrum disorders (ASD) is a complex and multifaceted neurobehavioral syndrome with no specific cause still identified, despite the worldwide increasing (prevalence for 1,000 children from 6.7 to 14.6, between 2000 and 2012). Many biological and instrumental markers have been suggested as potential predictive factors for the precocious diagnosis during infancy and/or pediatric age. Many studies reported structural and functional abnormalities in the autonomic system in subjects with ASD. Sleep problems in ASD are a prominent feature, having an impact on the social interaction of the patient. Considering the role of orexins (A and B) in wake-sleep circadian rhythm, we could speculate…

0301 basic medicineOrexin-APhysiologyAutism spectrum disorders (ASD); Heart rate (HR); Heart rate variability (HRV); Orexin-A; Oxidative stress; Physiology; Physiology (medical)Case ReportAutism spectrum disorders (ASD); Heart rate (HR); Heart rate variability (HRV); Orexin-A; Oxidative stressmedicine.disease_causelcsh:PhysiologyHeart rate (HR)03 medical and health sciences0302 clinical medicinePhysiology (medical)Heart ratemental disordersmedicineHeart rate variabilityCircadian rhythmlcsh:QP1-981business.industryPediatric agemedicine.diseaseAutism spectrum disorders (ASD)Pathophysiology030104 developmental biologyOxidative stressAutismOxidative streAutism spectrum disorders (ASD); Heart rate (HR); Heart rate variability (HRV); Orexin-A; Oxidative stress;Skin conductancebusinessNeuroscienceHeart rate variability (HRV)030217 neurology & neurosurgeryOxidative stress
researchProduct